David Happel
2023
In 2023, David Happel earned a total compensation of $2.7M as President and Chief Executive Officer at Sagimet Biosciences, a 59% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $329,725 |
|---|---|
| Salary | $502,894 |
| Stock Awards | $1,849,734 |
| Other | $3,564 |
| Total | $2,685,917 |
Happel received $1.8M in stock awards, accounting for 69% of the total pay in 2023.
Happel also received $329.7K in non-equity incentive plan, $502.9K in salary and $3.6K in other compensation.
Rankings
In 2023, David Happel's compensation ranked 342nd out of 2,647 executives tracked by ExecPay. In other words, Happel earned more than 87.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 342 out of 2,647 | 87th |
Division Manufacturing | 196 out of 1,447 | 87th |
Major group Chemicals And Allied Products | 136 out of 817 | 83rd |
Industry group Drugs | 133 out of 783 | 83rd |
Industry Pharmaceutical Preparations | 82 out of 555 | 85th |
Source: SEC filing on April 18, 2024.
Happel's colleagues
We found three more compensation records of executives who worked with David Happel at Sagimet Biosciences in 2023.